Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. Sanofi licenses Kiadis’s modified NK cell therapy for multiple myeloma
  2. Access to Covid-19 vaccines: MSF’s concerns about Gavi’s COVAX AMC
  3. Access to Covid-19 vaccines: deep dive into Gavi’s COVAX AMC
  4. Investing in late-stage companies: Forbion closes Growth Fund at €185m
  5. Exploring the promise of DUBs: Mission teams up with Pfizer

Company A-Z

Latest Content

Access to Covid-19 vaccines: MSF’s concerns about Gavi’s COVAX AMC

Gavi’s COVAX Facility and associated AMC aims to facilitate fair access to Covid-19 vaccines. However, global health charity MSF has apprehensions about various elements of the initiative, primarily linked to its view of Gavi’s previous AMC for PCVs. Let’s look deeper into MSF’s worries and its alternative recommendations.

Access to Covid-19 vaccines: deep dive into Gavi’s COVAX AMC

The only way the Covid-19 pandemic can be brought to an end is if everyone across the world has access to the right diagnostics, treatments, and importantly, vaccines. So the WHO launched the ACT-Accelerator; heading up its vaccine pillar is Gavi, which has created a COVAX Facility and advanced market commitment (AMC) mechanism for Covid-19 vaccines. How does this facility and AMC aim to help ensure equitable access to Covid-19 vaccines, once approved?

Tackling the next health crisis: pharma launches $1bn AMR Action Fund

Covid-19 is not the only public health threat facing the world. Drug-resistant bacterial infections have the potential to kill 10 million people a year by 2050 unless there are serious efforts to overcome the market failure in antibiotics development. IFPMA has brought together over 20 major pharma companies and public institutions to launch a $1bn fund to support antibiotic R&D.

Intellectual property in the time of Covid-19

Governments have been waiving common Intellectual Property laws in pursuit of a treatment for Covid-19, overriding patent protections and allowing sales of generic drugs. This is a concerning move for pharma companies struggling to navigate unclear rules, but could it change the R&D landscape forever? Abi Millar fins out more about IP during the Covid-19 crisis.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Close
Close
Close

Go Top